Allogene Therapeutics (ALLO) has a pipeline full of immunotherapy products it is developing to treat different types of cancer. Specifically, its platform relies on allogeneic CAR-T therapies. The latest partnership involves Notch Therapeutics and its own technology platform to treat cancer. Both companies will develop induced pluripotent stem cell (iPSC) AlloCAR therapy products using Notch's technology. This will help diversify Allogene's pipeline and give it access to treat a few types of hematological malignancies.
Partnership Advances Deep Dive Into New Type Of Technology
Allogene Therapeutics has formed a worldwide collaboration and license agreement